Bristol Myers Squibb and 2seventy bio announce that the Food and Drug Administration (FDA) will convene a virtual meeting of the Oncology Drug Advisory Committee (ODAC) on March 15, 2024, to review the data provided in support of the supplemental license application (sBLA) for Abecma (idecabtagene vicleucel) in relapsed or refractory multiple myeloma.

As a reminder, Abecma was recently approved in Japan for patients with relapsed or refractory multiple myeloma who have received at least two prior treatments.

Abecma has also received a positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Abecma's regulatory submissions for this patient population remain under review by the EMA and Swissmedic.

Copyright (c) 2024 CercleFinance.com. All rights reserved.